L-menthol

Phase 2Small molecule

RRegion Skane

L-menthol is one of 60 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseNot yet recruiting

AsthmaRecruiting

DesensitizationUnknown status

Interstitial Lung DiseasePhase 2

Not yet recruiting

AsthmaPhase 2

Recruiting

DesensitizationPreclinical

Unknown status

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

L-menthol

RRegion Skane

Phase 2

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Interstitial Lung Disease

NCT07398287

Phase 2Recruiting

Asthma

NCT07500974

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease

Not yet recruiting·RRegion Skane·Phase 2·NCT07398287·20 enrolled

Desensitization1 trial

Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol

Unknown status·—·N/A·NCT03132142·22 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease

Completed·RRegion Skane·Phase 2·NCT05888597·20 enrolled

Elderly1 trial

Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 3·NCT04593836·60 enrolled

Asthma1 trial

Effect of L-menthol on Breathlessness and Exercise Capacity in Asthma: a Randomized Crossover Trial

Recruiting·RRegion Skane·Phase 2·NCT07500974·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for L-menthol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-menthol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-menthol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Skane company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRegion Skane

L-menthol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Interstitial Lung Disease1 trial

Desensitization1 trial

Chronic Obstructive Pulmonary Disease1 trial

Elderly1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News